This study aims to explore the hypoglycemic effect of lyophilized broccoli microgreens on type 2 diabetes (T2D) in mice. The experiment lasted 18 weeks, including 1 week of adaptation (normal diet) and 17-week experimental period (high-fat diet). After ingestion of broccoli microgreens, the body weight and glucose homeostasis were improved. Meanwhile, the blood lipid status, antioxidant indexes, and inflammatory factors level were improved. Moreover, the insulin resistance and the pathological changes in mice organs were reversed. In addition, the composition of gut microbiota and the production of propionic acid in intestinal content were improved. Our experiment proved that broccoli microgreens have the ability to regulate T2D and improve symptoms of mice T2D induced by high-fat diet and streptozotocin (STZ). Practical applicationsFor years, the functionality of broccoli microgreens has attracted much attention. This article will prove the therapeutic effect of broccoli microgreens on T2D and explain its principle of action in the management of T2D.

L‐arabinose is a good and healthy food additive. This study was conducted to investigate the effect of L‐arabinose in a mouse model of type 2 diabetes mellitus (T2DM) induced by exposure to a high‐fat diet (HFD) and streptozotocin (STZ). The model mice received L‐arabinose at 20 and 60 mg (kg body weight [bw])−1d−1, metformin at 300 mg (kg bw)−1d−1 (positive control) or sterile water (control) via oral gavage. Compared with the model group, mice treated with L‐arabinose exhibited attenuated symptoms of diabetes mellitus, including a slower rate of body weight loss, increased homeostasis model assessment of β‐cell function index levels, decreased blood glucose, alleviation of steatosis, and repair of pancreatic islet cells. L‐arabinose also exerted an anti‐inflammatory effect and partially mitigated dyslipidemia. A 16S‐rRNA sequence analysis of the gut microbiota revealed that at the phylum level, treatment with L‐arabinose significantly reduced the ratio of Firmicutes to Bacteroidetes due to a decreased relative abundance of Firmicutes; at the genus level, it reversed the increase in the relative abundance of Allobaculum and the decrease abundance of Oscillospira caused by exposure to an HFD and STZ. And the model mice received L‐arabinose at 20 mg (kg bw)−1d−1 had a better effect on improving T2DM than the high‐dose group supplemented L‐arabinose at 60 mg (kg bw)−1d−1. These results strongly suggest L‐arabinose as an excellent candidate supplement to prevent or treat T2DM. Practical applications L‐arabinose, xylitol and sucralose are well‐known substitutes for sucrose. L‐arabinose has been reported to have beneficial effects on hyperglycemia, glycemic index, and fat accumulation. In this study, we found that low‐dose (20 mg (kg bw)−1d‐1) supplementation of L‐arabinose significantly improved glucose intolerance and gut microbiota incoordination in T2DM caused by HFD and STZ.

Metabolic associated fatty liver disease (MAFLD) is becoming the key factor in causing chronic liver disease over the world. Sulforaphane (SFN) has been proved to be effective in alleviating many...

Ulcerative colitis (UC) is becoming an increasingly serious health problem. This study aimed to investigate the effect of a newly isolated Lactobacillus species that produces feruloyl esterase (FAEb) on dextran sodium sulfate (DSS)-induced UC in mice. In this study, FAEb supplementation slowed body weight loss and mitigated colon length shortening, the severity of fecal occult blood, and increases in the disease activity index (DAI) in UC model mice. FAEb supplementation was also shown to reduce the expression of proinflammatory factors, increase the antioxidant capacity, improve the production of beneficial short-chain fatty acids (SCFAs), upregulate the expression of tight junction proteins, reduce the histopathological scores, and reduce mucous barrier damage in the gut. Furthermore, FAEb supplementation was shown to inhibit inflammatory NF-κB signaling pathway activity, increase the abundance of beneficial bacteria, and regulate the balance of microbiota in the gut. These results suggest that FAEb may serve as a potential probiotic to prevent and treat UC.